PMV Pharma Appoints Laurie Stelzer as Board Chair Ahead of NDA Filing
PMV Pharma board chair Rich Heyman will retire at the June 4, 2026 annual meeting, with director Laurie Stelzer—who joined in 2020—succeeding him. The shift coincides with enrollment in the registrational PYNNACLE trial and plans to file an NDA for rezatapopt in platinum-resistant ovarian cancer in Q1 2027.
1. Board Chair Transition
Rich Heyman, Ph.D., will retire as board chair and director at PMV Pharma’s 2026 annual meeting on June 4, 2026. Laurie Stelzer, a board member since 2020 with over 25 years of biopharma finance and business development leadership, will assume the chair role immediately thereafter.
2. Clinical Trial Progress
Enrollment continues in the registrational PYNNACLE trial evaluating rezatapopt monotherapy in patients with TP53 Y220C advanced solid tumors. The trial’s positive proof-of-concept data is viewed as critical to support the upcoming NDA submission.
3. NDA Submission Outlook
PMV Pharma plans to submit a New Drug Application for rezatapopt in platinum-resistant or refractory ovarian cancer patients with TP53 Y220C mutations in the first quarter of 2027. Success of this submission could unlock late-stage value and drive next-phase commercialization discussions.